Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
VTVT vTv Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: VTVT
Price (delayed)
$21.03
Market cap
$67.08M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.2
Enterprise value
$30.5M
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing oral, small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by programs for the treatment
Highlights
VTVT's debt has dropped by 68% year-on-year and by 21% since the previous quarter
The company's EPS has surged by 67% YoY and by 29% QoQ
VTVT's equity has soared by 149% year-on-year but it is down by 19% since the previous quarter
Key stats
What are the main financial stats of VTVT
Market
Valuations
Earnings
Shares outstanding
3.19M
Market cap
$67.08M
Enterprise value
$30.5M
Price to earnings (P/E)
N/A
Price to book (P/B)
5.5
Price to sales (P/S)
65.96
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
29.99
Revenue
$1.02M
Gross profit
$1.02M
Operating income
-$24.18M
Net income
-$18.46M
EBIT
-$18.36M
EBITDA
-$18.27M
Free cash flow
-$25.31M
Per share
Balance sheet
Liquidity
EPS
-$3.2
EPS diluted
-$3.2
Free cash flow per share
-$7.93
Book value per share
$3.82
Revenue per share
$0.32
TBVPS
$12
Total assets
$38.27M
Total liabilities
$23.97M
Debt
$169,000
Equity
$12.2M
Working capital
$32.92M
Debt to equity
0.01
Current ratio
7.34
Quick ratio
7.08
Net debt/EBITDA
2
Margins
Efficiency
Dividend
EBITDA margin
-1,796.8%
Gross margin
100%
Net margin
-1,815.3%
Operating margin
-2,377.6%
Return on assets
-40.6%
Return on equity
-114.5%
Return on invested capital
N/A
Return on capital employed
-55.5%
Return on sales
-1,805.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VTVT stock price
How has the vTv Therapeutics stock price performed over time
Intraday
-6.16%
1 week
1.11%
1 month
11.74%
1 year
-24.57%
YTD
52.3%
QTD
21.42%
Financial performance
How have vTv Therapeutics's revenue and profit performed over time
Revenue
$1.02M
Gross profit
$1.02M
Operating income
-$24.18M
Net income
-$18.46M
Gross margin
100%
Net margin
-1,815.3%
The net income is up by 9% year-on-year
VTVT's operating income is up by 5% YoY
Price vs fundamentals
How does VTVT's price correlate with its fundamentals
Growth
What is vTv Therapeutics's growth rate over time
Valuation
What is vTv Therapeutics stock price valuation
P/E
N/A
P/B
5.5
P/S
65.96
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
29.99
The company's EPS has surged by 67% YoY and by 29% QoQ
VTVT's equity has soared by 149% year-on-year but it is down by 19% since the previous quarter
VTVT's price to book (P/B) is 72% higher than its last 4 quarters average of 3.2
The P/S is 96% lower than the 5-year quarterly average of 1756.7 but 27% higher than the last 4 quarters average of 52.0
Efficiency
How efficient is vTv Therapeutics business performance
vTv Therapeutics's return on assets has surged by 61% YoY and by 14% QoQ
vTv Therapeutics's return on equity has surged by 57% QoQ
Dividends
What is VTVT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VTVT.
Financial health
How did vTv Therapeutics financials performed over time
VTVT's total assets is 60% greater than its total liabilities
The total liabilities has contracted by 19% YoY and by 5% from the previous quarter
VTVT's total assets is down by 11% since the previous quarter
VTVT's debt is 99% smaller than its equity
The debt to equity has soared by 150% year-on-year
VTVT's equity has soared by 149% year-on-year but it is down by 19% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.